Navigation Links
Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
Date:2/18/2011

conducted after 468 deaths.

An independent Data and Safety Monitoring Board (DSMB) will assess blinded safety measures and demographics at regular intervals throughout the study or as determined by the DSMB chair. The DSMB will also review interim irPFS data, unblinded at the group level, after 200 irPFS events. At the time of interim sample size review, the DSMB may recommend changes to the sample size or early termination of the study for efficacy or safety reasons as detailed in the protocol.

Key DatesFirst patient recruited Q3 2011

Interim data analysis* Q4 2012 - 1Q 2013

Final data analysis * Q4 2013 - 1Q 2014

*As an event driven study with adaptable design to have the flexibility after interim analysis to adjust patient size and study duration. Precise timelines are driven by these events of study patient progression free survival and/or overall survival and this can only be indicative.

Study SummaryThe purpose of this study is to determine whether CVac™ is effective in the treatment of Patients With Epithelial Ovarian Cancer (EOC) Following Optimal Debulking Surgery and First-line Chemotherapy as assessed by progression free survival or overall survival.

EndpointsPrimary Objectives

  • To assess the efficacy, in terms of immune-related progression-free survival (irPFS), of CVac™ as compared with placebo for maintenance treatment in patients with epithelial ovarian cancer (EOC) following optimal debulking surgery and first-line chemotherapy
  • To assess the efficacy, in terms of overall survival (OS), of CVac as compared with placebo for maintenance treatment in patients with EOC following optimal debulking surgery and first-line chemotherapy.

  • Secondary Objectives

  • To assess the safety and tolerability of CVac™ as compared with placebo
  • To assess health-related quality of life (QoL) related to CVac treatment as compared with plac
    '/>"/>

  • SOURCE Prima BioMed Ltd
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
    2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
    3. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
    4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
    5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
    6. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
    7. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
    8. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
    9. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
    10. Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM)
    11. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)...  Edison Nation Medical, the premier healthcare innovation ... Association for Respiratory Care ( AARC ), the ... Nation Medical, which brings 12+ years experience working ... innovation ideas, will work with AARC to assist ... respiratory therapists in bringing their product innovation ideas ...
    (Date:9/2/2014)... , Sept. 2, 2014  EMD Serono, Inc., a ... , announced today that Drew Young has ... Immunology. In this capacity, he will be responsible for ... Immunology franchise, including future products.   Bringing more ... marketing and sales efforts at pharmaceutical and biotech companies, ...
    (Date:9/2/2014)... 2014 Actavis plc (NYSE: ACT ... Administration (FDA) has accepted for filing Actavis, New Drug ... treatment of diarrhea and abdominal pain in men and ... NDA for eluxadoline has been granted priority review status ... "The NDA filing of eluxadoline marks ...
    Breaking Medicine Technology:Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 2EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 4Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 3Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 4
    ... (Nasdaq:  ARAY), a global leader in the field of ... institutions using CyberKnife radiosurgery in breast cancer treatment. These ... Fox Chase Cancer Center, will be presented at the ... Oncology (ASTRO) in San Diego from October 31 to ...
    ... 2010 Boehringer Ingelheim Pharmaceuticals, Inc. announced today results ... combination of two oral hepatitis C virus (HCV) compounds, ... BI 207127, with ribavirin reduced viral load below the ... The regimen did not include interferon through the first ...
    Cached Medicine Technology:CyberKnife Radiosurgery for Early-Stage Breast Cancer 2CyberKnife Radiosurgery for Early-Stage Breast Cancer 3CyberKnife Radiosurgery for Early-Stage Breast Cancer 4CyberKnife Radiosurgery for Early-Stage Breast Cancer 5CyberKnife Radiosurgery for Early-Stage Breast Cancer 6Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon 2Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon 3Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon 4
    (Date:9/2/2014)... New York, NY (PRWEB) September 02, 2014 ... and other new blood thinners is growing at a ... ) continue to mount in courts around the U.S., ... published in American Journal of Medicine, within a year ... to be prescribed Xarelto as warfarin, a blood thinner ...
    (Date:9/2/2014)... Complications are rare among breast cancer patients who ... However, the researchers did find that a ... risk for certain complications than a single mastectomy. ... cancer patients who had a single (64 percent) ... were followed for 30 days after surgery. ...
    (Date:9/2/2014)... In a large population-based study of randomly ... cognitive impairment (MCI) occurred twice more often in ... this strong association was only observed in middle-aged ... years) the association vanished. This study is published ... , The concept of MCI describes an intermediate ...
    (Date:9/2/2014)... (PRWEB) September 02, 2014 Medex ... location of their corporate headquarters in Coral Springs, Fla. ... have exceeded our business development objectives for the 2014 ... Neil Herbst. “Our industry has requested a higher level ... utilization reviews. Medex has delivered, and the industry has ...
    (Date:9/2/2014)... HealthDay Reporter TUESDAY, Sept. 2, ... driving force behind the rising rates of type 2 diabetes, ... from five national surveys spanning from 1976 through 2010 to ... be explained by factors such as changing distribution of race, ... that the prevalence of diabetes in men rose from about ...
    Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3
    ... , GLEN ALLEN, Va. , March 16 Star ... 10-K today with the Securities and Exchange Commission. The company reported net ... million in total sales for the previous year.  Cash and cash ... $6.5 million at year-end 2008. The net loss for 2009 totaled ...
    ... 16, 2010 The AIUM is pleased to ... AIUM to endorse the recent AIUM Training Guidelines ... guidelines allow for a several practitioners, including physicians, ... ultrasound examinations, marking significant promise for the future ...
    ... negative side effects, end-of-life care, review finds , ... that media reports slant towards bad news, but when ... may be overly optimistic, U.S. researchers suggest. , The ... highlight aggressive treatment and survival, with far less attention ...
    ... taking Plavix before surgery died soon after than those ... (HealthDay News) -- In a trial comparing two anti-clotting ... less likely to die than those given Plavix, researchers ... forming clots, but Plavix, the more popular drug, has ...
    ... GREENBELT, Md. , March 16 The following is being issued by LibertyProtection.net: , ... , , ... ... On ...
    ... Larry Minnix, President & CEO, American Association of Homes and Services for the Aging: , ... , , ... ... ...
    Cached Medicine News:Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 2Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 3Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 4Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 5Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 6Health News:Unprecedented AIUM training guidelines speak to future of musculoskeletal ultrasound 2Health News:Cancer Articles Tend to Focus on Positive Outcomes 2Health News:Newer Blood Thinner Beats Plavix for Bypass Patients 2Health News:Newer Blood Thinner Beats Plavix for Bypass Patients 3Health News:Court Hearing Thursday on Physicians' Challenge to 'Obamacare': Doctors Argue Against 'Arbitrary Power and Tyranny' 2Health News:Court Hearing Thursday on Physicians' Challenge to 'Obamacare': Doctors Argue Against 'Arbitrary Power and Tyranny' 3Health News:Court Hearing Thursday on Physicians' Challenge to 'Obamacare': Doctors Argue Against 'Arbitrary Power and Tyranny' 4Health News:Statement From Larry Minnix, President & CEO, American Association of Homes and Services for the Aging, on the Beginning of the Reconciliation Process for Health Reform Legislation 2Health News:Statement From Larry Minnix, President & CEO, American Association of Homes and Services for the Aging, on the Beginning of the Reconciliation Process for Health Reform Legislation 3
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: